Maravai LifeSciences reported Q3 2025 total revenues of $41.6 million, marked by a 7% growth in Biologic Safety Testing, but a significant 53% decline in Nucleic Acid Products year-over-year. Cost restructuring efforts are on track, aiming for positive adjusted EBITDA by 2026.

• Biologic Safety Testing revenue reached $16.3 million, benefiting from strong demand in core markets, particularly in the Americas and Europe.
• Nucleic Acid Products saw a 53% revenue decline, largely due to COVID-related order timing, though growth is anticipated in Q4.
• Management expects an annualized expense reduction exceeding $50 million and projects over $7 million in sequential adjusted EBITDA improvement in Q4.
• New product innovations like ModTail technology and IVT kits are gaining traction and could significantly enhance revenue streams moving forward.
• Cygnus remains a leader in the Biologic Safety Testing space, maintaining 100% market coverage in CAR-T and gene therapy products.